Why Bristol-Myers Is Soaring
The speculation centers around Bristol-Myers' cancer trial results.
Buying Pfizer Stock Brings a Great Dividend
Despite an average yield among Big Pharma, Pfizer offers plenty of advantages for income investors.
2 Red Flags for Merck's Type 2 Diabetes Blockbuster
A Fool breaks down the unexpected slide in Januvia/Janumet revenue in the first quarter.
Racing Toward the Next Hepatitis C Drug Approval
Johnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.